Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
Group 3 being ratio < 2, copy # >6, and IHC 2+
Answer from: Medical Oncologist at Academic Institution
If the case remains group 3 after an independent retesting with FISH and IHC as recommended by ASCO CAP guidelines, then the official recommendation is to treat it as HER2+ and use anti HER2 neoadjuvant therapy. However, some of these tumors are more luminal B than HER2 enriched on gene expression t...
Sign in or Register to read more